Recent developments in HIV-related kidney disease

HIV Therapy

Volumn 4, Issue 5, 2010, Pages 589-603

  Estrella, Michelle M ^a   Fine, Derek M ^a   Atta, Mohamed G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

glomerular filtration rate; HIV; HIVAN; kidney disease; serum creatinine; tenofovir

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; INDINAVIR; TENOFOVIR;

CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; GENETIC SUSCEPTIBILITY; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE COMPLEX DISEASE; INCIDENCE; KIDNEY FUNCTION; KIDNEY INJURY; NEPHROTOXICITY; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 78049486752     PISSN: 17584310     EISSN: None     Source Type: Journal    
DOI: 10.2217/hiv.10.42     Document Type: Review

References (115)

1. Franceschini N, Napravnik S, Eron JJ Jr, Szczech LA, Finn WF: Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int. 67(4), 1526-1531 (2005). (Pubitemid 40463131)
2. Choi AI, Li Y, Parikh C, Volberding PA, Shlipak MG: Long-term clinical consequences of acute kidney injury in the HIV-infected. Kidney Int. 78(5), 478-485 (2010). Large observational study, composed primarily of men, that showed an association between acute kidney injury in HIV-infected individuals and several long-term outcomes.
3. Wyatt CM, Arons RR, Klotman PE, Klotman ME: Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 20(4), 561-565 (2006).
4. Parkhie SM, Fine DM, Lucas GM, Atta MG: Characteristics of patients with HIV and biopsy-proven acute interstitial nephritis. Clin. J. Am. Soc. Nephrol. 5(5), 798-804 (2010).
5. Szczech LA, Grunfeld C, Scherzer R et al.: Microalbuminuria in HIV infection. AIDS 21(8), 1003-1009 (2007).
6. Fernando SK, Finkelstein FO, Moore BA, Weissman S: Prevalence of chronic kidney disease in an urban HIV infected population. Am. J. Med. Sci. 335(2), 89-94 (2008).
7. Jones CY, Jones CA, Wilson IB et al.: Cystatin C and creatinine in an HIV cohort: the Nutrition for Healthy Living Study. Am. J. Kidney Dis. 51(6), 914-924 (2008).
8. Szczech LA, Gupta SK, Habash R et al.: The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 66(3), 1145-1152 (2004).
9. Yadav A, Vallabu S, Kumar D et al.: HIVAN phenotype: consequence of epithelial mesenchymal transdifferentiation. Am. J. Physiol. Renal Physiol. 298(3), F734-F744 (2010).
10. Kumar D, Konkimalla S, Yadav A et al.: HIV-associated nephropathy: role of mammalian target of rapamycin pathway. Am. J. Pathol. 177(2), 813-821 (2010).
11. Kimmel PL, Phillips TM, Ferreira-Centeno A, Farkas-Szallasi T, Abraham AA, Garrett CT: HIV-associated immune-mediated renal disease. Kidney Int. 44(6), 1327-1340 (1993).
12. Estrella M, Fine DM, Gallant JE et al.: HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients. Clin. Infect. Dis. 43(3), 377-380 (2006).
13. Szczech LA, Hoover DR, Feldman JG et al.: Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin. Infect. Dis. 39(8), 1199-1206 (2004).
14. Estrella MM, Parekh RS, Abraham A et al.: The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women. J. Acquir. Immune Defic. Syndr. (2010) (In press).
15. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG: Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 121(5), 651-658 (2010).
16. George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG: Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS 24(3), 387-394 (2010).
17. Hsu CY, Ordonez JD, Chertow GM, Fan D, McCulloch CE, Go AS: The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 74(1), 101-107 (2008). (Pubitemid 351841887)
18. Lucas GM, Lau B, Atta MG, Fine DM, Keruly J, Moore RD: Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J. Infect. Dis. 197(11), 1548-1557 (2008).
19. Freedman BI, Soucie JM, Stone SM, Pegram S: Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am. J. Kidney Dis. 34(2), 254-258 (1999).
20. Bruggeman LA, Dikman S, Meng C, Quaggin SE, Coffman TM, Klotman PE: Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J. Clin. Invest. 100(1), 84-92 (1997).
21. Gharavi AG, Ahmad T, Wong RD et al.: Mapping a locus for susceptibility to HIV-1-associated nephropathy to mouse chromosome 3. Proc. Natl Acad. Sci. USA 101(8), 2488-2493 (2004).
22. Chan KT, Papeta N, Martino J et al.: Accelerated development of collapsing glomerulopathy in mice congenic for the HIVAN1 locus. Kidney Int. 75(4), 366-372 (2009).
23. Papeta N, Chan KT, Prakash S et al.: Susceptibility loci for murine HIV-associated nephropathy encode trans-regulators of podocyte gene expression. J. Clin. Invest. 119(5), 1178-1188 (2009). Using the transgenic mouse model for HIV-associated nephropathy (HIVAN), this study reports additional HIVAN susceptibility loci in mice and yields evidence of mechanisms underlying gene-environment interaction in HIVAN pathogenesis.
24. Quaggin SE: Genetic susceptibility to HIV-associated nephropathy. J. Clin. Invest. 119(5), 1085-1089 (2009).
25. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC: Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes 47(5), 821-830 (1998). (Pubitemid 28201814)
26. DeWan AT, Arnett DK, Atwood LD et al.: A genome scan for renal function among hypertensives: the HyperGEN study. Am. J. Hum. Genet. 68(1), 136-144 (2001).
27. Kopp JB, Smith MW, Nelson GW et al.: MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat. Genet. 40(10), 1175-1184 (2008). One of two original studies reporting the association of MYH9 variants and kidney disease among African-Americans. This study demonstrated a significant association between MYH9 E-1 risk haplotype and biopsy-proven HIVAN.
28. Kao WH, Klag MJ, Meoni LA et al.: MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat. Genet. 40(10), 1185-1192 (2008). Demonstrated a strong association between certain MYH9 risk variants and nondiabetic end-stage kidney disease among African-Americans.
29. Arrondel C, Vodovar N, Knebelmann B et al.: Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. J. Am. Soc. Nephrol. 13(1), 65-74 (2002).
30. Freedman BI, Hicks PJ, Bostrom MA et al.: Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int. 75(7), 736-745 (2009).
31. Freedman BI, Kopp JB, Winkler CA et al.: Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: the HyperGEN study. Am. J. Nephrol. 29(6), 626-632 (2009).
32. Freedman BI, Hicks PJ, Bostrom MA et al.: Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. Nephrol. Dial. Transplant. 24(11), 3366-3371 (2009).
33. Behar DM, Rosset S, Tzur S et al.: African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans. Hum. Mol. Genet. 19(9), 1816-1827 (2010).
34. Genovese G, Friedman DJ, Ross MD et al.: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329(5993), 841-845 (2010). Demonstrated that APOL1 variants are strongly associated with kidney disease among African-Americans and may account for the excess risk previously attributed to MYH9. It also demonstrated that the same APOL1 variants are protective against Trypanosoma.
35. Tzur S, Rosset S, Shemer R et al.: Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum. Genet. 128(3), 345-350 (2010).
36. Freedman BI, Kopp JB, Langefeld CD et al.: The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J. Am. Soc. Nephrol. (2010) (In press).
37. Winston JA, Klotman ME, Klotman PE: HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. Kidney Int. 55(3), 1036-1040 (1999).
38. Levin ML, Palella F, Shah S, Lerma E, Butter J, Kanwar YS: HIV-associated nephropathy occurring before HIV antibody seroconversion. Am. J. Kidney Dis. 37(5), E39 (2001).
39. Bruggeman LA, Ross MD, Tanji N et al.: Renal epithelium is a previously unrecognized site of HIV-1 infection. J. Am. Soc. Nephrol. 11(11), 2079-2087 (2000).
40. Eitner F, Cui Y, Hudkins KL et al.: Chemokine receptor CCR5 and CXCR4 expression in HIV-associated kidney disease. J. Am. Soc. Nephrol. 11(5), 856-867 (2000).
41. Zhong J, Zuo Y, Ma J et al.: Expression of HIV-1 genes in podocytes alone can lead to the full spectrum of HIV-1-associated nephropathy. Kidney Int. 68(3), 1048-1060 (2005).
42. Zuo Y, Matsusaka T, Zhong J et al.: HIV-1 genes vpr and nef synergistically damage podocytes, leading to glomerulosclerosis. J. Am. Soc. Nephrol. 17(10), 2832-2843 (2006).
43. Vallet-Pichard A, Pol S: Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. J. Hepatol. 44(1 Suppl.), S28-S34 (2006). (Pubitemid 43053870)
44. Wyatt CM, Malvestutto C, Coca SG, Klotman PE, Parikh CR: The impact of hepatitis C virus coinfection on HIV-related kidney disease: A systematic review and meta-analysis. AIDS 22(14), 1799-1807 (2008).
45. Mocroft A, Kirk O, Reiss P et al.: Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 24(11), 1667-1678 (2010). This observational study in the EuroSIDA cohort demonstrates the long-term renal effects of several antiretroviral medications. This study demonstrated that long-term exposure to atazanavir was associated with kidney function decline.
46. Yanik EL, Lucas GM, Vlahov D, Kirk GD, Mehta SH: HIV and proteinuria in an injection drug user population. Clin. J. Am. Soc. Nephrol. (2010) (In press).
47. Fine DM, Garg N, Haas M et al.: Cocaine use and hypertensive renal changes in HIV-infected individuals. Clin. J. Am. Soc. Nephrol. 2(6), 1125-1130 (2007).
48. Stengel B, Couchoud C: Chronic kidney disease prevalence and treated end-stage renal disease incidence: a complex relationship. J. Am. Soc. Nephrol. 17(8), 2094-2096 (2006).
49. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ: Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 58(1), 293-301 (2000).
50. Brown TT, Cole SR, Li X et al.: Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch. Intern. Med. 165(10), 1179-1184 (2005).
51. Seaberg EC, Munoz A, Lu M et al.: Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 19(9), 953-960 (2005). (Pubitemid 40834939)
52. Onen NF, Overton ET, Seyfried W et al.: Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin. Trials 11(2), 100-109 (2010).
53. Riddler SA, Smit E, Cole SR et al.: Impact of HIV infection and HAART on serum lipids in men. JAMA 289(22), 2978-2982 (2003).
54. Choi AI, Shlipak MG, Hunt PW, Martin JN, Deeks SG: HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS 23(16), 2143-2149 (2009).
55. Nguyen MT, Maynard SE, Kimmel PL: Misapplications of commonly used kidney equations: renal physiology in practice. Clin. J. Am. Soc. Nephrol. 4(3), 528-534 (2009).
56. Mehta RL, Kellum JA, Shah SV et al.: Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care 11(2), R31 (2007).
57. Gupta SK, Eustace JA, Winston JA et al.: Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis. 40(11), 1559-1585 (2005).
58. Siedner MJ, Atta MG, Lucas GM, Perazella MA, Fine DM: Poor validity of urine dipstick as a screening tool for proteinuria in HIV-positive patients. J. Acquir. Immune Defic. Syndr. 47(2), 261-263 (2008).
59. Levey AS, Coresh J, Balk E et al.: National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann. Intern. Med. 139(2), 137-147 (2003).
60. Ginsberg JM, Chang BS, Matarese RA, Garella S: Use of single voided urine samples to estimate quantitative proteinuria. N. Engl. J. Med. 309(25), 1543-1546 (1983).
61. Price CP, Newall RG, Boyd JC: Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review. Clin. Chem. 51(9), 1577-1586 (2005).
62. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16(1), 31-41 (1976).
63. Levey AS, Bosch JP, Lewis JB et al.: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann. Intern. Med. 130, 461-470 (1999).
64. Levey AS, Greene T, Kusek JW et al.: A simplified equation to predict glomerular filtration rate from serum creatinine. J. Am. Soc. Nephrol. 11, 115A (2000).
65. Levey AS, Coresh J, Greene T et al.: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Intern. Med. 145(4), 247-254 (2006).
66. Levey AS, Stevens LA, Schmid CH et al.: A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150(9), 604-612 (2009). This study by the Chronic Kidney Disease-Epidemiology Collaboration generated a new more accurate and precise equation for estimating kidney function in the general population: the CKD-EPI equation.
67. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG: Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann. Intern. Med. 141(12), 929-937 (2004).
68. Bostom AG, Kronenberg F, Ritz E: Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J. Am. Soc. Nephrol. 13(8), 2140-2144 (2002).
69. Huang E, Hewitt RG, Shelton M, Morse GD: Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease. Pharmacotherapy 16(2), 222-229 (1996). (Pubitemid 26087932)
70. Noormohamed SE, Katseres JK, Stapleton JT: Poor correlation between published methods to predict creatinine clearance and measured creatinine clearance in asymptomatic HIV infected individuals. Ren. Fail. 20(4), 627-633 (1998).
71. Smith BL, Sarnoski TP, Dennis S, Luke DR: Failure of predicted creatinine clearance equations in HIV-seropositive patients. Int. J. Clin. Pharmacol. Ther. Toxicol. 30(10), 394-399 (1992).
72. Barraclough K, Er L, Ng F, Harris M, Montaner J, Levin A: A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population. Nephron Clin. Pract. 111(1), c39-c48 (2009).
73. Shlipak MG, Wassel Fyr CL, Chertow GM et al.: Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J. Am. Soc. Nephrol. 17(1), 254-261 (2006).
74. Kottgen A, Selvin E, Stevens LA, Levey AS, Van Lente F, Coresh J: Serum cystatin C in the united states: The Third National Health and Nutrition Examination Survey (NHANES III). Am. J. Kidney Dis. 51(3), 385-394 (2008).
75. Stevens LA, Coresh J, Schmid CH et al.: Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am. J. Kidney Dis. 51(3), 395-406 (2008).
76. Stevens LA, Schmid CH, Greene T et al.: Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 75(6), 652-660 (2009). This observational study includes detailed analyses showing several extra-renal factors which influence serum cystatin C levels in HIV-uninfected persons.
77. Odden MC, Scherzer R, Bacchetti P et al.: Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch. Intern. Med. 167(20), 2213-2219 (2007).
78. Mauss S, Berger F, Kuschak D et al.: Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients. Antivir. Ther. 13(8), 1091-1095 (2008).
79. Mocroft A, Wyatt C, Szczech L et al.: Interruption of antiretroviral therapy is associated with increased plasma cystatin C. AIDS 23(1), 71-82 (2009).
80. Bernard AM, Moreau D, Lauwerys R: Comparison of retinol-binding protein and b2-microglobulin determination in urine for the early detection of tubular proteinuria. Clin. Chim. Acta 126(1), 1-7 (1982).
81. Norden AG, Scheinman SJ, Deschodt-Lanckman MM et al.: Tubular proteinuria defined by a study of dent's (CLCN5 mutation) and other tubular diseases. Kidney Int. 57(1), 240-249 (2000).
82. Price RG: The role of NAG (N-acetyl-β-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin. Nephrol. 38(Suppl. 1), S14-S19 (1992).
83. Kuwabara T, Mori K, Mukoyama M et al.: Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int. 75(3), 285-294 (2009).
84. Hall AM, Edwards SG, Lapsley M et al.: Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. Am. J. Kidney Dis. 54(6), 1034-1042 (2009).
85. Landro L, Damas JK, Flo TH et al.: Decreased serum lipocalin-2 levels in human immunodeficiency virus-infected patients: Increase during highly active anti-retroviral therapy. Clin. Exp. Immunol. 152(1), 57-63 (2008). (Pubitemid 351347544)
86. Soler-Garcia AA, Johnson D, Hathout Y, Ray PE: Iron-related proteins: candidate urine biomarkers in childhood HIV-associated renal diseases. Clin. J. Am. Soc. Nephrol. 4(4), 763-771 (2009).
87. Paragas N, Nickolas TL, Wyatt C et al.: Urinary NGAL marks cystic disease in HIV-associated nephropathy. J. Am. Soc. Nephrol. 20(8), 1687-1692 (2009).
88. Tabatabai S, Sperati CJ, Atta MG et al.: Predictors of complication after percutaneous ultrasound-guided kidney biopsy in HIV-infected individuals: possible role of hepatitis C and HIV co-infection. Clin. J. Am. Soc. Nephrol. 4(11), 1766-1773 (2009).
89. Choi AI, Rodriguez RA, Bacchetti P et al.: Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin. Infect. Dis. 45(12), 1633-1639 (2007).
90. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD: Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 18(3), 541-546 (2004).
91. Yahaya I, Uthman AO, Uthman MM: Interventions for HIV-associated nephropathy. Cochrane Database Syst. Rev. 4, CD007183 (2009).
92. Hammer SM, Eron JJ Jr, Reiss P et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300(5), 555-570 (2008).
93. Eustace JA, Nuermberger E, Choi M, Scheel PJ Jr, Moore R, Briggs WA: Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int. 58(3), 1253-1260 (2000).
94. Cihlar T, Ho ES, Lin DC, Mulato AS: Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20(4-7), 641-648 (2001).
95. Ray AS, Cihlar T, Robinson KL et al.: Mechanism of active renal tubular efflux of tenofovir. Antimicrob. Agents Chemother. 50(10), 3297-3304 (2006).
96. Kohler JJ, Hosseini SH, Hoying-Brandt A et al.: Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab. Invest. 89(5), 513-519 (2009).
97. Peyriere H, Reynes J, Rouanet I et al.: Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J. Acquir. Immune Defic. Syndr. 35(3), 269-273 (2004). (Pubitemid 38280652)
98. Mathew G, Knaus SJ: Acquired Fanconi's syndrome associated with tenofovir therapy. J. Gen. Intern. Med. 21(11), C3-C5 (2006).
99. + adults: report of three cases and literature review. J. Bone Miner. Res. 19(5), 714-721 (2004).
100. Di Biagio A, Rosso R, Monteforte P, Russo R, Rovetta G, Viscoli C: Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report. J. Med. Case Reports 3, 8136 (2009).
101. Perrot S, Aslangul E, Szwebel T, Caillat-Vigneron N, Le Jeunne C: Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. J. Clin. Rheumatol. 15(2), 72-74 (2009).
102. Rollot F, Nazal EM, Chauvelot-Moachon L et al.: Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin. Infect. Dis. 37(12), e174-e176 (2003).
103. Coca S, Perazella MA: Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am. J. Med. Sci. 324(6), 342-344 (2002).
104. Gallant JE, Staszewski S, Pozniak AL et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292(2), 191-201 (2004).
105. Izzedine H, Hulot JS, Vittecoq D et al.: Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. data from a double-blind randomized active-controlled multicentre study. Nephrol. Dial. Transplant. 20(4), 743-746 (2005).
106. Arribas JR, Pozniak AL, Gallant JE et al.: Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J. Acquir. Immune Defic. Syndr. 47(1), 74-78 (2008).
107. Jones R, Stebbing J, Nelson M et al.: Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J. Acquir. Immune Defic. Syndr. 37(4), 1489-1495 (2004).
108. Gallant JE, Parish MA, Keruly JC, Moore RD: Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin. Infect. Dis. 40(8), 1194-1198 (2005).
109. Gallant JE, Moore RD: Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 23(15), 1971-1975 (2009).
110. Rodriguez-Novoa S, Labarga P, Soriano V et al.: Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin. Infect. Dis. 48(11), e108-e116 (2009).
111. Young B, Buchacz K, Moorman A, Wood KC, Brooks JT; HIV Outpatient Study (HOPS) Investigators: Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study. AIDS Patient Care STDS 23(8), 589-592 (2009).
112. Marroni M, Gaburri M, Mecozzi F, Baldelli F: Acute interstitial nephritis secondary to the administration of indinavir. Ann. Pharmacother. 32(7-8), 843-844 (1998).
113. Brodie SB, Keller MJ, Ewenstein BM, Sax PE: Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. AIDS 12(18), 2433-2437 (1998).
114. Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB: Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's adverse event reporting system. AIDS 21(9), 1215-1218 (2007).
115. Izzedine H, M'rad MB, Bardier A, Daudon M, Salmon D: Atazanavir crystal nephropathy. AIDS 21(17), 2357-2358 (2007).